ReviewMedical2026
Advanced cannabidiol delivery platforms: smart biomaterials, controlled release systems, and 3D-bioprinted therapeutic technologies.
Shabbir A.; Parvinzadeh Gashti M. · Journal of drug targeting · 2026
Research summary
**Background & Methods**
This is a comprehensive review article examining advanced drug delivery platforms for cannabidiol (CBD), a non-psychoactive cannabinoid from Cannabis sativa L. The review synthesizes current literature on innovative biomaterial technologies, controlled-release systems, and 3D bioprinting approaches designed to overcome CBD's inherent pharmaceutical limitations.
**Key Findings**
• Advanced polymeric biomaterials (PLGA, PEG derivatives, chitosan, alginate, and cellulose-based systems) significantly enhance CBD stability and enable sustained release profiles, addressing poor aqueous solubility and rapid metabolism that currently limit clinical translation.
• Nano- and microstructured delivery systems—including liposomes, nanoparticles, nanoemulsions, microspheres, and electrospun nanofibers—demonstrate enhanced bioavailability and enable targeted cellular-level delivery, with 3D bioprinting technology enabling fabrication of patient-specific scaffolds for precision medicine applications.
• Stimuli-responsive platforms (pH-, temperature-, enzyme-, and externally triggered systems) facilitate on-demand drug release in diseased microenvironments, with demonstrated applications across antimicrobial therapy, wound healing, tumor-targeted cancer therapy, immunomodulation, and regenerative medicine.
**Dosage & Administration**
Not reported. This review does not present clinical dosing data, as it focuses on delivery platform design and optimization rather than clinical trial outcomes.
**Safety & Adverse Effects**
Not reported. The review does not discuss safety profiles or adverse effects of CBD-based delivery systems, concentrating instead on pharmaceutical optimization and biomedical applications.
**Evidence Quality**
This is a narrative review article rather than a primary research study, representing a lower level of evidence (Level 5). Key limitations include lack of systematic methodology, absence of meta-analysis or quantitative synthesis, and reliance on selected literature synthesis. The review acknowledges significant translational challenges including drug loading efficiency variability, stability issues across different platforms, scalability concerns, and regulatory barriers. While the article comprehensively addresses emerging technologies, it does not provide clinical outcome data or comparative efficacy evidence. The focus on future perspectives (AI-guided design, personalized nanomedicine) indicates this remains an evolving field with limited clinical translation to date.
Summary generated by DeepWeed from the published abstract. See the original paper for full methods and results.
Journal
Journal of drug targeting
Ask how this study fits the wider evidence — across 26,000+ papers.
Ask DeepWeed
More recent cannabis research
This page summarises published research for informational purposes only — it isn't medical advice. Always refer to the original publication for full methods, results and limitations.